EUVIMEDEUVIMED entdecken
Übersichtsarbeit

20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight

Satyam Singh, Sushabhan Sadhukhan, Avinash Sonawane

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2023-11 · 1878 (6) · 188967

DOI: 10.1016/j.bbcan.2023.188967 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023-11. Verfasst von Satyam Singh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Madhya Pradesh 453 552, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 193 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) actively involves in modulation of various cancer progression related mechanisms including angiogenesis, differentiation and migration. Therefore, targeting EGFR has surfaced as a prominent approach for the treatment of several types of cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, glioblastoma. Various first, second and third generation of EGFR tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated effectiveness as an anti-cancer therapeutics. However, rapid development of drug resistance and mutations still remains a major challenge for the EGFR-TKIs therapy. Overcoming from intrinsic and acquired resistance caused by EGFR mutations warrants the further exploration of alternative strategies and discovery of novel inhibitors. In this review, we delve into the breakthrough discoveries have been made in previous 20 years, and discuss the currently ongoing efforts aimed to circumvent the chemo-resistance. We also highlight the new challenges, limitations and future directions for the development of improved therapeutic approaches such as fourth-generation EGFR-TKIs, peptides, nanobodies, PROTACs etc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansGefitinibProtein Kinase InhibitorsDrug Resistance, NeoplasmErbB Receptors

Stichwörter der Autor:innen

BsAbsDrug resistanceEGFREGFR-TKIsOsimertinibPROTACs

Substanzen

GefitinibProtein Kinase InhibitorsErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Madhya Pradesh 453 552, India.
  • Department of Chemistry, Indian Institute of Technology Palakkad, Kerala 678 623, India; Department of Biological Sciences & Engineering, Indian Institute of Technology Palakkad, Kerala 678 623, India. Electronic addres…
  • Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Madhya Pradesh 453 552, India. Electronic address: asonawane@iiti.ac.in.

Zitieren

APA

Singh, S., Sadhukhan, S., & Sonawane, A. (2023). 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1878(6), 188967. https://doi.org/10.1016/j.bbcan.2023.188967

Vancouver

Singh S, Sadhukhan S, Sonawane A. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023;1878(6):188967. doi:10.1016/j.bbcan.2023.188967

BibTeX
@article{Singh2023,
  author = {Singh, Satyam and Sadhukhan, Sushabhan and Sonawane, Avinash},
  title = {20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2023},
  volume = {1878},
  number = {6},
  pages = {188967},
  doi = {10.1016/j.bbcan.2023.188967}
}
Kostenlos starten →